Subscribe
Dabarti CGI / Shutterstock.com
24 September 2024FeaturesBiotechnologySam Andrews

Preventative IP for preventative pharma healthcare

The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead scores win in fake HIV drug dispute
19 September 2024   New York court grants Gilead’s contempt motion | Defendant violated asset freeze order by selling and mortgaging properties


Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024

More on this story

Americas
Gilead scores win in fake HIV drug dispute
19 September 2024   New York court grants Gilead’s contempt motion | Defendant violated asset freeze order by selling and mortgaging properties

More on this story

Americas
Gilead scores win in fake HIV drug dispute
19 September 2024   New York court grants Gilead’s contempt motion | Defendant violated asset freeze order by selling and mortgaging properties

More features

Court denies Regeneron bid to halt copy of blockbuster eye drug
Interview: Klaus Grabinski, UPC Court of Appeal president
Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy